[go: up one dir, main page]

AR044400A1 - Procesos para la preparacion de derivados de pirimidina - Google Patents

Procesos para la preparacion de derivados de pirimidina

Info

Publication number
AR044400A1
AR044400A1 ARP040101733A ARP040101733A AR044400A1 AR 044400 A1 AR044400 A1 AR 044400A1 AR P040101733 A ARP040101733 A AR P040101733A AR P040101733 A ARP040101733 A AR P040101733A AR 044400 A1 AR044400 A1 AR 044400A1
Authority
AR
Argentina
Prior art keywords
preparation
hydrogen
processes
compounds
unsubstituted
Prior art date
Application number
ARP040101733A
Other languages
English (en)
Original Assignee
Ciba Sc Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Sc Holding Ag filed Critical Ciba Sc Holding Ag
Publication of AR044400A1 publication Critical patent/AR044400A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un proceso para la preparación de compuestos de la fórmula (1), a partir de la reacción de los compuestos seleccionados del grupo de fórmulas (2), para formar un compuesto de la fórmula (3), en las cuales en cada caso R1, R2 y R3 son cada uno, independientemente entre sí, un radical orgánico sin sustituir o sustituido; R4 es hidrógeno, alquilo C1-8, alcoxilo C1-8, fenoxilo o benciloxilo sin sustituir o sustituidos, o halógeno; Y1 e Y2 son cada uno, independientemente del otro, hidrógeno o un grupo protector, o Y1 e Y2 conjuntamente son un puente de protección; y X1 es hidrógeno, un radical orgánico o un catión; y también compuestos intermedios novedosos.
ARP040101733A 2003-05-21 2004-05-19 Procesos para la preparacion de derivados de pirimidina AR044400A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03405355 2003-05-21

Publications (1)

Publication Number Publication Date
AR044400A1 true AR044400A1 (es) 2005-09-14

Family

ID=33462271

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101733A AR044400A1 (es) 2003-05-21 2004-05-19 Procesos para la preparacion de derivados de pirimidina

Country Status (2)

Country Link
AR (1) AR044400A1 (es)
WO (1) WO2004103977A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
KR100888408B1 (ko) 2001-07-13 2009-03-13 아스트라제네카 유케이 리미티드 아미노피리미딘 화합물의 제조 방법
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
ATE448209T1 (de) 2002-12-16 2009-11-15 Astrazeneca Uk Ltd Verfahren zur herstellung von pyrimidinverbindungen
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CN100351240C (zh) * 2005-01-19 2007-11-28 安徽省庆云医药化工有限公司 瑞舒伐他汀钙的合成方法
KR100945763B1 (ko) * 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
KR20090113920A (ko) * 2005-10-03 2009-11-02 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 부분입체 이성질체 정제
WO2007099561A1 (en) * 2006-02-27 2007-09-07 Cadila Healthcare Limited Process for preparing rosuvastatin calcium
WO2009157014A2 (en) * 2008-01-30 2009-12-30 Cadila Healthcare Limited A process for preparing hmg-coa reductase inhibitors and intermediates
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
CN101955463B (zh) * 2010-08-04 2012-01-04 重庆博腾制药科技股份有限公司 瑞舒伐他汀钙中间体的制备方法
HU230987B1 (hu) * 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
CN102617481A (zh) * 2012-03-16 2012-08-01 湖南欧亚生物有限公司 一种瑞舒伐他汀钙的制备方法
CN102633727A (zh) * 2012-04-01 2012-08-15 浙江工业大学 一种2-甲硫基-4-(4-氟苯基)-6-异丙基-嘧啶-5-羧酸甲酯的合成方法
CN103113356A (zh) * 2013-03-07 2013-05-22 上海现代制药股份有限公司 一种罗苏伐他汀钙的中间体的制备方法
US9850213B2 (en) * 2013-11-25 2017-12-26 Jiangxi Boya Seehot Pharmaceutical Co., Ltd. Method for preparing rosuvastatin sodium
HUE037976T2 (hu) 2014-03-07 2018-09-28 Asymchem Lab Tianjin Co Ltd A Rozuvasztatin-kalcium elõállítására szolgáló intermedier vegyület és az elõállítás módszer
CN103804414B (zh) * 2014-03-07 2016-04-13 凯莱英医药集团（天津）股份有限公司 用于制备瑞舒伐他汀钙的中间体化合物以及由其制备瑞舒伐他汀钙的方法
CN104059024B (zh) * 2014-06-16 2016-04-06 浙江大学 瑞舒伐他汀中间体的制备方法及中间体化合物
CN105175345B (zh) * 2015-09-22 2018-05-22 上海应用技术学院 一种制备瑞舒伐他汀中间体的方法
CN106397335A (zh) * 2016-08-31 2017-02-15 湖北祥云(集团)化工股份有限公司 瑞舒伐他汀中间体的制备方法
CN108191772A (zh) * 2017-12-28 2018-06-22 江苏悦兴医药技术有限公司 瑞舒伐他汀钙中间体杂质的合成方法
CN115819408B (zh) * 2022-10-21 2024-09-06 宿迁阿尔法科技有限公司 一种高选择性合成瑞舒伐他汀关键中间体的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3105354B2 (ja) * 1991-07-03 2000-10-30 三井化学株式会社 顕色剤組成物、水性懸濁液及びそれを用いた感圧複写紙用顕色シート

Also Published As

Publication number Publication date
WO2004103977A3 (en) 2005-01-06
WO2004103977A2 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
AR044400A1 (es) Procesos para la preparacion de derivados de pirimidina
AR034792A1 (es) Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, su preparacion y su aplicacion en terapeutica
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
ES2221440T3 (es) Derivados de acido aminofenoxiacetico como neuroprotectores.
CO5050332A1 (es) Composiciones fungicidas que comprenden 2-metoxibenzofenonas
EA200800285A1 (ru) Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk
CO5580803A2 (es) Derivados de piperidin-bencensulfonamida
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
DE60307179D1 (de) Vor UV-Strahlen schützende Zusammensetzungen
DK1781683T3 (da) Fremgangsmåde til fremstilling af 17-vinyl-triflater som halvfabrikata
CO4990929A1 (es) Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8
AR041297A1 (es) Derivados de 4-pirrolidino- fenil- bencil eter
BR9612099A (pt) Processo para preparar um composto derivado de piperidina, regioisÈmero, processo para preparar um regioisÈmero, derivado de ácido 4-( alfa,alfa, di-substuìdo) toluico e 4- (alfa, alfa-di-não substitìdo) toluico.
AR040489A1 (es) Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen
AR044177A1 (es) Proceso para la preparacion de trans-isomeros de derivados de la difenilazetidinona
ECSP045278A (es) Compuestos de oxo-azabicíclicos
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
NO20054787L (no) Indenderivater som farmasotiske midler
PE20030705A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
CO5601030A2 (es) Derivados de quinolinona/benzoxazinona y usos de los mismos
CO5540385A2 (es) Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienen
BR0212982A (pt) Processo para preparar um composto, e, composto

Legal Events

Date Code Title Description
FB Suspension of granting procedure